Semarion, a University of Cambridge spin-out, has secured $3.8 million in funding to advance its innovative drug screening technology. The company combines materials engineering and cell biology to address unmet needs in the pharmaceutical industry. The round was led by Parkwalk, with participation from several other notable investors.
